Management Team
Dr. Peter Kash is a co-founder and Vice-Chairman of TargImmune Therapeutics (Switzerland). He was formerly a co-founder and partner and Chairman of Two River Group and President of Riverbank Capital Securities specializing in creating and financing several biotech companies including Kite Pharma, Edgemont Pharmaceuticals, and Intercept Pharmaceuticals. He has cofounded more than a dozen biotech companies and raised in excess of $2 billion in private/public financing, creating more than $20 billion in peak aggregate market value. Dr. Kash has worked on Wall Street for 30 years including at Shearson Lehman Hutton and Paramount Capital. At Paramount he co-founded and financed PolaRx Biopharmaceuticals; developing the first cancer drug from China, Trisenox approved by the FDA. The portfolio companies have received a total of 6 FDA approvals to date.
From 1990-1992 he was an Associate Professor of Marketing at Polytechnic University. During 1996-2000 he was an Adjunct Professor of Entrepreneurship at the Wharton Business School. During 2000-2002 he was a Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo and in 2015 a Visiting Professor at Hebrew University. He has frequently lectured and served as a Keynote Speaker worldwide in many of the 70 countries he has visited.
His education includes a B.S. in Management Science from S.U.N.Y. Binghamton and an MBA in International Banking and Finance from the Lubin School of Business at Pace University. He holds a Doctorate in Education at The Azrieli Graduate School of Yeshiva University. Dr. Kash completed post graduate classes on Making Boards of Directors More Effective at Harvard Business School.
He has authored several books including the international best seller Make Your Own Luck, (Prentice Hall), now in 8 languages distributed in more than 70 countries and (international bestseller Freedom From Disease (St. Martin’s Press). His third book Take Two Tablets Medicine from the Bible. You might have seen Peter as a television host for FNN’s and as a guest on CNBC, Fox and Friends, Show, WB11, or with Dr. Oz Radio Show, and more recently at his first Tedx lecture in London 2019.
Dr. Peter Kash is a co-founder and Vice-Chairman of TargImmune Therapeutics (Switzerland). He was formerly a co-founder and partner and Chairman of Two River Group and President of Riverbank Capital Securities specializing in creating and financing several biotech companies including Kite Pharma, Edgemont Pharmaceuticals, and Intercept Pharmaceuticals. He has cofounded more than a dozen biotech companies and raised in excess of $2 billion in private/public financing, creating more than $20 billion in peak aggregate market value. Dr. Kash has worked on Wall Street for 30 years including at Shearson Lehman Hutton and Paramount Capital. At Paramount he co-founded and financed PolaRx Biopharmaceuticals; developing the first cancer drug from China, Trisenox approved by the FDA. The portfolio companies have received a total of 6 FDA approvals to date.
From 1990-1992 he was an Associate Professor of Marketing at Polytechnic University. During 1996-2000 he was an Adjunct Professor of Entrepreneurship at the Wharton Business School. During 2000-2002 he was a Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo and in 2015 a Visiting Professor at Hebrew University. He has frequently lectured and served as a Keynote Speaker worldwide in many of the 70 countries he has visited.
His education includes a B.S. in Management Science from S.U.N.Y. Binghamton and an MBA in International Banking and Finance from the Lubin School of Business at Pace University. He holds a Doctorate in Education at The Azrieli Graduate School of Yeshiva University. Dr. Kash completed post graduate classes on Making Boards of Directors More Effective at Harvard Business School.
He has authored several books including the international best seller Make Your Own Luck, (Prentice Hall), now in 8 languages distributed in more than 70 countries and (international bestseller Freedom From Disease (St. Martin’s Press). His third book Take Two Tablets Medicine from the Bible. You might have seen Peter as a television host for FNN’s and as a guest on CNBC, Fox and Friends, Show, WB11, or with Dr. Oz Radio Show, and more recently at his first Tedx lecture in London 2019.
Dr. Colby Kash is the Chief Executive Officer and co-founder of Camelot BioCapital, a biotechnology venture studio and advisory firm focused on advancing innovative technologies that increase the human healthspan. As a leader in the field, Dr. Kash directs a team of more than 15 professionals, including physicians, scientists, and investment experts, in developing and financing groundbreaking healthcare solutions. Camelot’s portfolios have collectively raised over $100 million for the research and development of novel therapeutics targeting cancer and other life-threatening conditions.
Dr. Kash is also the author of the Amazon bestseller, The Autoimmune Plague: How to Regain Sovereignty Over Your Body and Life. Trained as a wellness and longevity functional medicine practitioner, he is a sought-after keynote speaker on healthcare topics and has been featured in prominent organizations such as the, the University of Florida, Young Presidents’ Organization, Authority Magazine, Thrive Global, The Epoch Times, Chiropractic Economics Magazine, and Health Professional Radio. In 2024, Dr. Kash was recognized as a 40 Under 40 Honoree by the University of Florida Alumni Association.
Dr. Kash holds a Doctor of Chiropractic and a Master of Science in Applied Clinical Nutrition from the Northeast College of Health Sciences, along with a Bachelor of Science in Applied Physiology and Kinesiology from the University of Florida. His expertise is further supported by advanced certifications, including the ADAPT Functional Medicine certification, American College of Sports Medicine Certified Exercise Physiologist, and National Academy of Sports Medicine Certified Personal Trainer credentials.
Dr. Colby Kash is the Chief Executive Officer and co-founder of Camelot BioCapital, a biotechnology venture studio and advisory firm focused on advancing innovative technologies that increase the human healthspan. As a leader in the field, Dr. Kash directs a team of more than 15 professionals, including physicians, scientists, and investment experts, in developing and financing groundbreaking healthcare solutions. Camelot’s portfolios have collectively raised over $100 million for the research and development of novel therapeutics targeting cancer and other life-threatening conditions.
Dr. Kash is also the author of the Amazon bestseller, The Autoimmune Plague: How to Regain Sovereignty Over Your Body and Life. Trained as a wellness and longevity functional medicine practitioner, he is a sought-after keynote speaker on healthcare topics and has been featured in prominent organizations such as the, the University of Florida, Young Presidents’ Organization, Authority Magazine, Thrive Global, The Epoch Times, Chiropractic Economics Magazine, and Health Professional Radio. In 2024, Dr. Kash was recognized as a 40 Under 40 Honoree by the University of Florida Alumni Association.
Dr. Kash holds a Doctor of Chiropractic and a Master of Science in Applied Clinical Nutrition from the Northeast College of Health Sciences, along with a Bachelor of Science in Applied Physiology and Kinesiology from the University of Florida. His expertise is further supported by advanced certifications, including the ADAPT Functional Medicine certification, American College of Sports Medicine Certified Exercise Physiologist, and National Academy of Sports Medicine Certified Personal Trainer credentials.
Mr. Matthew Bronfman is the Chairman and CEO of BHB Holdings, a private investment firm with numerous interests. He served as Chairman of Bronfman Rothschild, a Washington, D.C. based Registered Investment Advisor. In addition, Mr. Bronfman controls the IKEA franchise in Israel and has numerous real estate holdings there and in the U.S. He also serves as Chairman of Lincoln Avenue Capital an affordable housing investment firm, and Bronfman LLC, a provider of growth capital for private companies. Prior to starting BHB, Mr. Bronfman was a partner at ACI Capital, private equity firm in NYC. ACI portfolio companies included Accent Energy, Sundance Catalogue, and Jenny Craig. Prior to that, Mr. Bronfman was the Chairman and Chief Executive Officer of Sterling Cellular Holdings, LP, a privately held cellular telephone company. Previously, he was employed by Goldman Sachs & Co. and Cadillac Fairview Corporation Limited. He received a BA from Williams College in 1981 and an MBA from Harvard Business School in 1985.
Mr. Matthew Bronfman is the Chairman and CEO of BHB Holdings, a private investment firm with numerous interests. He served as Chairman of Bronfman Rothschild, a Washington, D.C. based Registered Investment Advisor. In addition, Mr. Bronfman controls the IKEA franchise in Israel and has numerous real estate holdings there and in the U.S. He also serves as Chairman of Lincoln Avenue Capital an affordable housing investment firm, and Bronfman LLC, a provider of growth capital for private companies. Prior to starting BHB, Mr. Bronfman was a partner at ACI Capital, private equity firm in NYC. ACI portfolio companies included Accent Energy, Sundance Catalogue, and Jenny Craig. Prior to that, Mr. Bronfman was the Chairman and Chief Executive Officer of Sterling Cellular Holdings, LP, a privately held cellular telephone company. Previously, he was employed by Goldman Sachs & Co. and Cadillac Fairview Corporation Limited. He received a BA from Williams College in 1981 and an MBA from Harvard Business School in 1985.
Dr. Josh Sharan is a distinguished physician-scientist with deep expertise in drug development and therapeutic venture capital. As the Chief Scientific Officer at Camelot BioCapital, Dr. Sharan leads the identification and evaluation of promising therapeutic candidates, overseeing technical diligence and acquisition efforts to drive innovation in the biotech landscape.
Dr. Sharan is also a co-founder of TMAB Therapeutics and Emerald Biotherapeutics, where he provides strategic and operational support to portfolio companies.
Dr. Sharan has a Doctor of Osteopathic Medicine degree from Nova Southeastern University. He has professional affiliations with the American Society of Gene & Cell Therapy and The Antibody Society.
Dr. Josh Sharan is a distinguished physician-scientist with deep expertise in drug development and therapeutic venture capital. As the Chief Scientific Officer at Camelot BioCapital, Dr. Sharan leads the identification and evaluation of promising therapeutic candidates, overseeing technical diligence and acquisition efforts to drive innovation in the biotech landscape.
Dr. Sharan is also a co-founder of TMAB Therapeutics and Emerald Biotherapeutics, where he provides strategic and operational support to portfolio companies.
Dr. Sharan has a Doctor of Osteopathic Medicine degree from Nova Southeastern University. He has professional affiliations with the American Society of Gene & Cell Therapy and The Antibody Society.
Dr. Friedland is a physician with over 25 years of experience in clinical medicine and an international advisor to many Fortune and Forbes global companies. She consults with healthcare, biotech, corporate, and financial institutions. Among her roles, Dr. Friedland is the head of Business Development at Firebrick Pharma (Australia), senior consultant to TargImmune Therapeutics (Basel, Switzerland), co-founder, and director of FFD Capital LLC (USA), and Medical Officer for the Anti- Inflammaging Company (Dubai, UAE). Dr. Friedland is also a non-executive director on several Healthcare boards. An author of seven healthcare-related bestsellers with a long career in television
and health media, she has developed public health and disease management programs in Asia, USA, Australia, Africa, and the UK and delivered keynote addresses in more than 30 countries.
Dr. Friedland is a physician with over 25 years of experience in clinical medicine and an international advisor to many Fortune and Forbes global companies. She consults with healthcare, biotech, corporate, and financial institutions. Among her roles, Dr. Friedland is the head of Business Development at Firebrick Pharma (Australia), senior consultant to TargImmune Therapeutics (Basel, Switzerland), co-founder, and director of FFD Capital LLC (USA), and Medical Officer for the Anti- Inflammaging Company (Dubai, UAE). Dr. Friedland is also a non-executive director on several Healthcare boards. An author of seven healthcare-related bestsellers with a long career in television
and health media, she has developed public health and disease management programs in Asia, USA, Australia, Africa, and the UK and delivered keynote addresses in more than 30 countries.
Dr. Rice graduated with honors from Nova Southeastern University’s College of Osteopathic Medicine. As Vice President, with a background in both business and healthcare, Dr. Rice is responsible for identifying and pursuing new business opportunities. He assists all C-suite personnel and spends much of his focus in the preclinical and clinical development of the company’s therapeutics. Through a combination of strategic planning, market analysis, and scientific acumen, Dr. Rice advances Camelot’s therapeutic programs.
Dr. Rice graduated with honors from Nova Southeastern University’s College of Osteopathic Medicine. As Vice President, with a background in both business and healthcare, Dr. Rice is responsible for identifying and pursuing new business opportunities. He assists all C-suite personnel and spends much of his focus in the preclinical and clinical development of the company’s therapeutics. Through a combination of strategic planning, market analysis, and scientific acumen, Dr. Rice advances Camelot’s therapeutic programs.
Mr. Veerappan is a seasoned entrepreneur, investor, and executive with over two decades of experience across the pharmaceutical, technology, media, and finance sectors. He currently serves as Chairman and CEO of Sapphire Pharma LLC, a pharmaceutical company focused on strategic innovation, and is the Founder and Principal of Tydings Capital LLC, a private investment firm. He also holds the role of Chairman at Munidex Inc., overseeing its strategic growth and operations.
His extensive consulting and technical background spans a who’s who of the pharmaceutical industry, having worked with major global companies including Teva, Bristol-Myers Squibb, Pfizer, Novartis, Johnson & Johnson, Boehringer Ingelheim, Merck, Roche, Faulding, and Sanofi.
A passionate entrepreneur with a global footprint, he has founded, owned, and managed several enterprises in the U.S. and internationally, including Mtech Consulting Group, Spatial Comps, and Fitness One. His career also includes cross-industry experience at firms such as Lifesciences International, Jacobs Engineering, GEA, and Glatt.
Beyond business, he has contributed to media as an Associate Producer of the Netflix series Brown Nation and is actively involved in philanthropic efforts. He serves as a Trustee of VAMS, a not-for-profit Montessori school in Southern India, reflecting his long-standing commitment to education and community development.
With a career defined by innovation, leadership, and cross-disciplinary impact, he continues to focus on creating value and transforming industries on a global scale.
Mr. Veerappan is a seasoned entrepreneur, investor, and executive with over two decades of experience across the pharmaceutical, technology, media, and finance sectors. He currently serves as Chairman and CEO of Sapphire Pharma LLC, a pharmaceutical company focused on strategic innovation, and is the Founder and Principal of Tydings Capital LLC, a private investment firm. He also holds the role of Chairman at Munidex Inc., overseeing its strategic growth and operations.
His extensive consulting and technical background spans a who’s who of the pharmaceutical industry, having worked with major global companies including Teva, Bristol-Myers Squibb, Pfizer, Novartis, Johnson & Johnson, Boehringer Ingelheim, Merck, Roche, Faulding, and Sanofi.
A passionate entrepreneur with a global footprint, he has founded, owned, and managed several enterprises in the U.S. and internationally, including Mtech Consulting Group, Spatial Comps, and Fitness One. His career also includes cross-industry experience at firms such as Lifesciences International, Jacobs Engineering, GEA, and Glatt.
Beyond business, he has contributed to media as an Associate Producer of the Netflix series Brown Nation and is actively involved in philanthropic efforts. He serves as a Trustee of VAMS, a not-for-profit Montessori school in Southern India, reflecting his long-standing commitment to education and community development.
With a career defined by innovation, leadership, and cross-disciplinary impact, he continues to focus on creating value and transforming industries on a global scale.
Joe LeBas is the President, Managing Director, and Founder of Concorde Group Holdings, LLC, a global, technology-driven commercial real estate (CRE) development firm that owns nearly 1 million square feet of commercial retail, office, industrial, and executive housing assets across the Southeastern United States, United Arab Emirates, and India.
Mr. LeBas is an accomplished technology and commercial real estate entrepreneur with a strong track record in market creation and profitable growth. He brings a proven history of building dynamic and innovative businesses across multiple industries and geographies, including four successful software company exits to Fortune 750 acquirers, generating over $500 million in returns to investors.
His ventures have spanned data science, big data, machine learning, and data virtualization, many of which served as early precedents for what is now widely recognized as artificial intelligence (AI)—a strong strategic pillar of Camelot’s biotech focus.
As a first-generation wealth creator, Mr. LeBas has also established the Carswell Family Office, which concentrates on investments in global operating companies, clean tech, biotech, and software, with a geographic emphasis on the U.S. and UAE.
Joe LeBas is the President, Managing Director, and Founder of Concorde Group Holdings, LLC, a global, technology-driven commercial real estate (CRE) development firm that owns nearly 1 million square feet of commercial retail, office, industrial, and executive housing assets across the Southeastern United States, United Arab Emirates, and India.
Mr. LeBas is an accomplished technology and commercial real estate entrepreneur with a strong track record in market creation and profitable growth. He brings a proven history of building dynamic and innovative businesses across multiple industries and geographies, including four successful software company exits to Fortune 750 acquirers, generating over $500 million in returns to investors.
His ventures have spanned data science, big data, machine learning, and data virtualization, many of which served as early precedents for what is now widely recognized as artificial intelligence (AI)—a strong strategic pillar of Camelot’s biotech focus.
As a first-generation wealth creator, Mr. LeBas has also established the Carswell Family Office, which concentrates on investments in global operating companies, clean tech, biotech, and software, with a geographic emphasis on the U.S. and UAE.
Dr. Banks is a 25-year veteran of the pharmaceutical industry with a proven record of clinical, regulatory, and entrepreneurial success. Dr. Banks has served as a drug development expert, corporate R&D adviser, company creator, and venture-capital adviser to more than 350 pharmaceutical and biotechnology companies (from start-ups to multinationals). He has contributed to the successful FDA approval of 24 drugs and biologics (NDAs/BLAs), including HUMIRA® (adalimumab) for rheumatoid arthritis as well as therapies for oncology, metabolic, pulmonary, gastrointestinal, and rare diseases. While at Salix Pharmaceuticals, Dr. Banks led the hepatic encephalopathy program for rifaximin that secured FDA approval and was key in Salix’s $14 billion acquisition by Valeant Pharmaceuticals.
In 2008, Dr. Banks founded Nuventra Pharma Sciences and, as Chief Executive Officer and principal consultant, grew the firm from a start-up to a 120-person organization before its 2021 acquisition by CATO SMS (now Allucent). Under his leadership, Nuventra became an industry leader in clinical pharmacology, pharmacokinetics, and model-informed drug development across every major therapeutic area. Dr. Banks also co-founded and served as Chief Operating Officer of 1st Order Pharmaceuticals, Inc., which in-licensed an IND-ready potassium-channel opener for epilepsy from Valeant Pharmaceuticals in 2015. The molecule was acquired by Xenon Pharmaceuticals in 2017 and is now in Phase 3 clinical trials.
An active member of the global entrepreneurial community, Dr. Banks joined Entrepreneurs’ Organization (EO) in 2012. He currently serves on the board of directors of the EO Raleigh-Durham chapter and is also a member of the EO New York chapter.
Dr. Banks is now Chief Executive Officer of BiFormyx, a biopharmaceutical company pioneering dual-payload antibody-drug conjugates for oncology. In this role he blends deep drug-development expertise with a proven ability to scale companies from the C-suite.
Dr. Banks is a 25-year veteran of the pharmaceutical industry with a proven record of clinical, regulatory, and entrepreneurial success. Dr. Banks has served as a drug development expert, corporate R&D adviser, company creator, and venture-capital adviser to more than 350 pharmaceutical and biotechnology companies (from start-ups to multinationals). He has contributed to the successful FDA approval of 24 drugs and biologics (NDAs/BLAs), including HUMIRA® (adalimumab) for rheumatoid arthritis as well as therapies for oncology, metabolic, pulmonary, gastrointestinal, and rare diseases. While at Salix Pharmaceuticals, Dr. Banks led the hepatic encephalopathy program for rifaximin that secured FDA approval and was key in Salix’s $14 billion acquisition by Valeant Pharmaceuticals.
In 2008, Dr. Banks founded Nuventra Pharma Sciences and, as Chief Executive Officer and principal consultant, grew the firm from a start-up to a 120-person organization before its 2021 acquisition by CATO SMS (now Allucent). Under his leadership, Nuventra became an industry leader in clinical pharmacology, pharmacokinetics, and model-informed drug development across every major therapeutic area. Dr. Banks also co-founded and served as Chief Operating Officer of 1st Order Pharmaceuticals, Inc., which in-licensed an IND-ready potassium-channel opener for epilepsy from Valeant Pharmaceuticals in 2015. The molecule was acquired by Xenon Pharmaceuticals in 2017 and is now in Phase 3 clinical trials.
An active member of the global entrepreneurial community, Dr. Banks joined Entrepreneurs’ Organization (EO) in 2012. He currently serves on the board of directors of the EO Raleigh-Durham chapter and is also a member of the EO New York chapter.
Dr. Banks is now Chief Executive Officer of BiFormyx, a biopharmaceutical company pioneering dual-payload antibody-drug conjugates for oncology. In this role he blends deep drug-development expertise with a proven ability to scale companies from the C-suite.
Tomer is the Israeli General Partner at Camelot BioCapital.
He is a serial entrepreneur and venture builder specializing in healthcare, biotech, and deep tech innovation.
His first equity deal was with NYX Technologies, a leading neuroscience tech company he co-founded in 2016, where he has served as CEO and chairman since its inception.
Prior to founding NYX, Tomer was the executive director of the Technion’s BizTEC accelerator, where he directly supported more than 60 deep tech ventures.
He now leads the Technion’s BizTEC alumni organization, representing a network of over 2,000 tech entrepreneurs built over two decades of innovation. Tomer is an 8200 EISP alumnus, a Merage Institute alumnus, and an XTC finalist.
Tomer is the Israeli General Partner at Camelot BioCapital.
He is a serial entrepreneur and venture builder specializing in healthcare, biotech, and deep tech innovation.
His first equity deal was with NYX Technologies, a leading neuroscience tech company he co-founded in 2016, where he has served as CEO and chairman since its inception.
Prior to founding NYX, Tomer was the executive director of the Technion’s BizTEC accelerator, where he directly supported more than 60 deep tech ventures.
He now leads the Technion’s BizTEC alumni organization, representing a network of over 2,000 tech entrepreneurs built over two decades of innovation. Tomer is an 8200 EISP alumnus, a Merage Institute alumnus, and an XTC finalist.
As Relationship Manager at Camelot BioCapital, Shantal plays a key role in advancing the firm’s mission to support breakthrough technologies that extend human healthspan. She leads investor engagement, cultivates company communications, and connects aligned capital partners with opportunities across biotechnology, healthcare technology, and related sectors.
Before joining Camelot, Shantal built a global career in international sales, partnerships, and hospitality, working across Canada, New Zealand, Spain, and the United States. Her background includes collaboration with some of the world’s most prominent sports and entertainment brands, including the Toronto Raptors, Toronto Maple Leafs, Miami Dolphins, and Formula 1—developing a sharp instinct for authentic, impact-driven relationship building.
She now brings that global perspective, energy, and people-first mindset to venture investing, helping visionary founders and investors bring transformative ideas to life.
As Relationship Manager at Camelot BioCapital, Shantal plays a key role in advancing the firm’s mission to support breakthrough technologies that extend human healthspan. She leads investor engagement, cultivates company communications, and connects aligned capital partners with opportunities across biotechnology, healthcare technology, and related sectors.
Before joining Camelot, Shantal built a global career in international sales, partnerships, and hospitality, working across Canada, New Zealand, Spain, and the United States. Her background includes collaboration with some of the world’s most prominent sports and entertainment brands, including the Toronto Raptors, Toronto Maple Leafs, Miami Dolphins, and Formula 1—developing a sharp instinct for authentic, impact-driven relationship building.
She now brings that global perspective, energy, and people-first mindset to venture investing, helping visionary founders and investors bring transformative ideas to life.
Ohad Shahar is the Systems Manager at Camelot BioCapital, where he leads the design and implementation of internal systems that support the firm’s end-to-end investment process. He focuses on building scalable, structured workflows that enhance deal flow management, team coordination, and decision-making across the organization.
Earlier in his career, Ohad served as Head of Medicine in a Special Forces unit, where he directed medical operations, led advanced training programs, and helped integrate innovative medical technologies into real-world missions.
With a background at the intersection of disciplined field leadership and startup operations, Ohad brings a systems-driven mindset and executional rigor to his work at Camelot.
Ohad Shahar is the Systems Manager at Camelot BioCapital, where he leads the design and implementation of internal systems that support the firm’s end-to-end investment process. He focuses on building scalable, structured workflows that enhance deal flow management, team coordination, and decision-making across the organization.
Earlier in his career, Ohad served as Head of Medicine in a Special Forces unit, where he directed medical operations, led advanced training programs, and helped integrate innovative medical technologies into real-world missions.
With a background at the intersection of disciplined field leadership and startup operations, Ohad brings a systems-driven mindset and executional rigor to his work at Camelot.
Dr. Kunis is a Research Analyst at Camelot BioCapital with a Doctor of Osteopathic Medicine degree from Nova Southeastern University and a Masters in Medical Education. Currently completing a general surgery residency, he brings a robust clinical foundation to his role. He is also pursuing a post-doctoral fellowship in the Clinical Trials Department at a major cancer center. With extensive experience in data collection, statistical analysis, and peer review, Dr. Kunis bridges clinical insight with rigorous research methodologies to support the advancement of innovative therapies.
Dr. Kunis is a Research Analyst at Camelot BioCapital with a Doctor of Osteopathic Medicine degree from Nova Southeastern University and a Masters in Medical Education. Currently completing a general surgery residency, he brings a robust clinical foundation to his role. He is also pursuing a post-doctoral fellowship in the Clinical Trials Department at a major cancer center. With extensive experience in data collection, statistical analysis, and peer review, Dr. Kunis bridges clinical insight with rigorous research methodologies to support the advancement of innovative therapies.
Cedrick is a Certified Public Accountant (CPA) with over 11 years of professional experience, specializing in accounting, tax, and financial management. Cedrick began his career as an auditor at PwC and has since held various roles including accounting manager, controller, tax consultant, bookkeeper, and market researcher in several multinational organizations. He has a strong command of accounting standards and procedures in the United States, Australia, New Zealand, Hong Kong, and Singapore, particularly in financial statement preparation and audit.
Cedrick is a Certified Public Accountant (CPA) with over 11 years of professional experience, specializing in accounting, tax, and financial management. Cedrick began his career as an auditor at PwC and has since held various roles including accounting manager, controller, tax consultant, bookkeeper, and market researcher in several multinational organizations. He has a strong command of accounting standards and procedures in the United States, Australia, New Zealand, Hong Kong, and Singapore, particularly in financial statement preparation and audit.
Dr. Pombo-Villar is currently the CTO of TargImmune Therapeutics AG in Switzerland. He held the post of CEO position from its seed stage in 2017 until August 2021. Under his leadership, the company developed the innovative targeted immunooncology platform and its lead project into IND-enabling studies, established the operations in Basel, and raised over CHF 47 million. He studied Chemistry at the University of Warwick where he obtained his Ph.D., MSc, and BSc. He completed his post-doctoral studies at the ETH Zürich in prebiotic chemistry and organic chemistry under Prof. A Eschenmoser. He spent 23 years in drug discovery and development at Sandoz and Novartis, as well as held several roles in business development functions, and was head of alliance management at the Novartis Institute for Biomedical Research (NIBR), where he focused on creating and managing the company’s collaborative efforts. Prior to joining TargImmune, he was chief operations officer and a Board Member of Oxford BioTherapeutics (OBT) overseeing the UK -based biotech’s newly created development operations in Basel. Dr. Pombo-Villar is a Fellow of the Royal Society of Chemistry, a member of several scientific societies, and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US).
Dr. Pombo-Villar is currently the CTO of TargImmune Therapeutics AG in Switzerland. He held the post of CEO position from its seed stage in 2017 until August 2021. Under his leadership, the company developed the innovative targeted immunooncology platform and its lead project into IND-enabling studies, established the operations in Basel, and raised over CHF 47 million. He studied Chemistry at the University of Warwick where he obtained his Ph.D., MSc, and BSc. He completed his post-doctoral studies at the ETH Zürich in prebiotic chemistry and organic chemistry under Prof. A Eschenmoser. He spent 23 years in drug discovery and development at Sandoz and Novartis, as well as held several roles in business development functions, and was head of alliance management at the Novartis Institute for Biomedical Research (NIBR), where he focused on creating and managing the company’s collaborative efforts. Prior to joining TargImmune, he was chief operations officer and a Board Member of Oxford BioTherapeutics (OBT) overseeing the UK -based biotech’s newly created development operations in Basel. Dr. Pombo-Villar is a Fellow of the Royal Society of Chemistry, a member of several scientific societies, and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US).
Dr. Mitchell is Co-Founder, President, and Chairman of iOncologi, Inc., a biotechnology ‘spinout’ company from the University of Florida (UF) specializing in immuno-oncology. Dr. Mitchell is the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery at UF. He serves as Director of the UF Clinical Translational Science Institute (CTSI) and Co-Director of the Preston A. Wells, Jr. Center for Brain Tumor Therapy. Under Dr. Mitchell’s leadership, the Wells Brain Tumor Center has grown to one of the largest brain tumor centers in the United States, with over 100 fulltime employees dedicated to brain tumor research and clinical care and drawing patients from over 39 states and internationally for novel brain tumor treatments. He graduated from the Medical Scientist Training Program (MD/Ph.D.) at Duke University Medical Center and completed postgraduate training in pathology and neurooncology research prior to joining the faculty at Duke in 2005 as an Assistant Professor. He has advanced discoveries from his laboratory through the successful issuance of six FDA-approved investigational new drugs (IND) applications and has led the clinical evaluation of several novel brain tumor immunotherapies through ten first-in-human clinical trials and multi-center phase 2 studies. His research has been supported by the NIH, Department of Defense, and numerous private funding agencies Dr. Mitchell is an inventor of over 25 filed patents for novel cancer immunotherapies, several of which have been licensed by pharmaceutical companies for commercial development.
Dr. Mitchell is Co-Founder, President, and Chairman of iOncologi, Inc., a biotechnology ‘spinout’ company from the University of Florida (UF) specializing in immuno-oncology. Dr. Mitchell is the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery at UF. He serves as Director of the UF Clinical Translational Science Institute (CTSI) and Co-Director of the Preston A. Wells, Jr. Center for Brain Tumor Therapy. Under Dr. Mitchell’s leadership, the Wells Brain Tumor Center has grown to one of the largest brain tumor centers in the United States, with over 100 fulltime employees dedicated to brain tumor research and clinical care and drawing patients from over 39 states and internationally for novel brain tumor treatments. He graduated from the Medical Scientist Training Program (MD/Ph.D.) at Duke University Medical Center and completed postgraduate training in pathology and neurooncology research prior to joining the faculty at Duke in 2005 as an Assistant Professor. He has advanced discoveries from his laboratory through the successful issuance of six FDA-approved investigational new drugs (IND) applications and has led the clinical evaluation of several novel brain tumor immunotherapies through ten first-in-human clinical trials and multi-center phase 2 studies. His research has been supported by the NIH, Department of Defense, and numerous private funding agencies Dr. Mitchell is an inventor of over 25 filed patents for novel cancer immunotherapies, several of which have been licensed by pharmaceutical companies for commercial development.